

## Special Issue

# New Advances in Brain Remodeling and Recovery in Cerebrovascular Diseases

### Message from the Guest Editor

Old age is associated with an enhanced susceptibility to neurodegenerative diseases. Despite the initial hope that cell-based therapies may stimulate restorative processes in the degenerative brain, it is now recognized that the aging processes may promote an unfavorable environment for such treatments. In the last several years, many groups have focused on exploiting brain plasticity, that is preserved to some extent even in the old brains, to enhance endogenous repair mechanisms of the brain after insults, such as traumatic brain injury or cerebral ischemia. Brain plasticity allows continuous remodeling of brain structure and function during aging and disease. People who incur a brain injury are prone to the development of neurodegenerative and neuroendocrine disorders. Thus, a traumatic brain injury (TBI) can trigger pathological changes within brain circuits and might lead to long-term cognitive and neuropsychological impairments. This Special Issue of *Biomedicines*, will provide up-to-date information on molecular, cellular, and behavioral events associated with brain remodelling in response to aging and disease and open new avenues for treatment options.

### Guest Editor

Prof. Dr. Aurel Popa-Wagner

1. Chair of Vascular Neurology and Dementia, Essen University Medical School, Essen, Germany
2. Experimental Research Center for Normal and Pathological Aging Director, University of Medicine and Pharmacy of Craiova, Craiova, Romania

### Deadline for manuscript submissions

closed (30 September 2023)



## Biomedicines

an Open Access Journal  
by MDPI

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/140162](https://mdpi.com/si/140162)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLUS / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).